Merck & Co. agreed to buy Cubist Pharmaceuticals Inc. for $8.4 billion in cash to add products to help fight the growing threat of drug-resistant bacteria.

Merck will begin a $102-a-share tender offer for Cubist, the companies said in a statement today. The price is 37 percent above Cubist’s closing level on Dec. 5. Including net debt, the deal is valued at about $9.5 billion.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.